ROG has been the subject of a number of other research reports. JPMorgan Chase & Co. reissued a buy rating and issued a target price on shares of Roche in a research report on Thursday, November 2nd. Goldman Sachs Group set a CHF 325 target price on Roche and gave the stock a buy rating in a research report on Monday, September 11th. Berenberg Bank set a CHF 260 target price on Roche and gave the stock a neutral rating in a research report on Monday, November 20th. Credit Suisse Group set a CHF 300 target price on Roche and gave the stock a buy rating in a research report on Monday, September 11th. Finally, set a CHF 203 target price on Roche and gave the stock a sell rating in a research report on Friday, October 20th. Three analysts have rated the stock with a sell rating, eight have given a hold rating and nine have assigned a buy rating to the company’s stock. The company has an average rating of Hold and an average price target of CHF 263.42.
Shares of Roche (VTX:ROG) traded up CHF 0.30 during trading on Monday, reaching CHF 249.80. 1,740,000 shares of the company were exchanged, compared to its average volume of 1,500,000. The company has a market cap of $216,110.00 and a PE ratio of 22.20. Roche has a 52 week low of CHF 226.10 and a 52 week high of CHF 273.
COPYRIGHT VIOLATION NOTICE: This article was first posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this article on another publication, it was stolen and reposted in violation of US and international copyright law. The original version of this article can be viewed at https://ledgergazette.com/2018/01/09/roche-rog-given-a-chf-260-price-target-at-ubs-group.html.
Roche Company Profile
Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.
Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.